Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.93M | 16.96M | 14.61M | 17.97M | 17.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.93M | 16.96M | 14.61M | 17.97M | 17.05M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 14.93M | 16.96M | 14.61M | 17.97M | 17.05M |
| SG&A Expenses | 11.39M | 12.85M | 13.68M | 13.41M | 14.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.45M | 40.50M | 44.46M | 42.16M | 49.82M |
| Operating Income | -24.53M | -23.54M | -29.85M | -24.19M | -32.77M |
| Income Before Tax | -23.95M | -22.71M | -29.19M | -23.05M | -31.52M |
| Income Tax Expenses | -1.31M | -416.00K | -363.00K | -395.00K | -363.00K |
| Earnings from Continuing Operations | -22.64M | -22.29M | -28.82M | -22.66M | -31.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.64M | -22.29M | -28.82M | -22.66M | -31.16M |
| EBIT | -24.53M | -23.54M | -29.85M | -24.19M | -32.77M |
| EBITDA | -23.32M | -22.65M | -29.38M | -23.59M | -32.15M |
| EPS Basic | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 |
| Normalized Basic EPS | -0.70 | -0.65 | -0.89 | -0.68 | -0.93 |
| EPS Diluted | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 |
| Normalized Diluted EPS | -0.70 | -0.65 | -0.89 | -0.68 | -0.93 |
| Average Basic Shares Outstanding | 21.36M | 21.24M | 21.19M | 21.18M | 21.17M |
| Average Diluted Shares Outstanding | 21.36M | 21.24M | 21.19M | 21.18M | 21.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |